import type { ReportEntry } from '@/data/healthcareReportTypes';

const SLUG = 'gcc-vaccines-market-report';

/**
 * Curated copy for the GCC vaccines programmatic report.
 * SEO target: regional comparator for country vaccine market queries.
 * Market sizing: BioNixus market analysis, 2026 (~USD 1.18B → ~USD 2.06B 2030, ~17.9% CAGR).
 */
type OverrideCopy = Partial<ReportEntry> & Pick<ReportEntry, 'slug'>;

export const GCC_VACCINES_COPY: OverrideCopy = {
  slug: SLUG,
  title: 'GCC Vaccine Market Report 2026',
  metaTitle: 'GCC Vaccine Market 2026 | Size & NIP | BioNixus',
  metaDescription:
    'GCC vaccine market ~USD 1.18B in 2026 (BioNixus analysis), ~17.9% CAGR: Saudi NIP + Hajj, UAE travel vaccines, conjugate tenders—Gulf decision-ready intelligence.',
  modifiedDate: '2026-08-14',
  heroLead:
    'The GCC vaccine market is a six-country procurement and schedule arena: Saudi Arabia’s National Immunization Program and Hajj/Umrah requirements set the regional pace, the UAE adds a private and travel-vaccine engine, and Kuwait, Qatar, Bahrain, and Oman run distinct ministry schedules and cold-chain logistics.',
  summaryPara1:
    'BioNixus sizes the GCC vaccine market at roughly USD 1.18 billion in 2026, advancing toward about USD 2.06 billion by 2030 at roughly 17.9% CAGR. Saudi Arabia anchors government NIP and pilgrimage-led volume; the UAE contributes a dual public–private and travel-vaccine mix; smaller Gulf states add childhood-schedule and adult-expansion volume through ministry tenders. Growth concentrates in HPV, adult pneumococcal and influenza, RSV entrants, and conjugate/meningococcal programmes tied to mass gatherings and school mandates. Sizing reflects BioNixus market analysis, 2026.',
  summaryPara2:
    'Use this report with the [GCC pharmaceutical market report 2026](/gcc-pharma-market-report-2026) for macro pharma context, the [Saudi Arabia vaccine market report](/market-reports/saudi-arabia-vaccines-market-report) for NIP and Hajj depth, the [UAE vaccine market report](/market-reports/uae-vaccines-market-report) for travel and private-channel dynamics, the [Egypt vaccine market report](/market-reports/egypt-vaccines-market-report) for a MENA scale comparator, [vaccines research](/healthcare-market-research/therapy/vaccines) for programme design, and the [healthcare market research hub](/healthcare-market-research) to commission bilingual fieldwork. BioNixus vaccine trackers sit alongside biologics, biosimilars, oncology, and rare-disease insight programmes.',
  marketAccessNotes:
    'Saudi MOH NIP and NUPCO tendering plus Hajj/Umrah mandatory vaccination; UAE MOHAP/DHA/DOH schedules with strong private and travel channels; Kuwait, Qatar, Bahrain, and Oman ministry childhood schedules and influenza/HPV expansion; conjugate and meningococcal tender bundling; cold-chain and mass-campaign logistics as operational gates',
  fieldIntelligenceParagraph:
    'BioNixus field programmes treat GCC vaccines as a schedule-and-procurement market with sharp country differences. We pair public-health and immunisation-committee interviews with tender and cold-chain depth, and we size pilgrimage-driven Saudi demand separately from UAE private/travel volume so Gulf strategies do not apply a single channel model. Adult immunisation (HPV, pneumococcal, influenza, RSV) is tracked as the shared growth corridor across all six states.',
  commercialOutlookParagraph:
    'Through 2030 the outlook is strong-growth and policy-led. Pediatric bases remain tender-driven; upside comes from adult schedule expansion, continued mass-gathering requirements in Saudi Arabia, and private/travel resilience in the UAE. Manufacturers should stress-test volume by country schedule decisions and tender cycles rather than applying a uniform GCC curve.',
  methodologyParagraph:
    'Methodology combines BioNixus market analysis for six-market sizing and CAGR bands with desk review of national immunisation programmes, ministry tender guidance, and pilgrimage health requirements, plus primary modules where data is available. Outputs support market access and commercial leadership and do not constitute regulatory or clinical advice.',
  faqs: [
    {
      question: 'How large is the GCC vaccine market in 2026?',
      answer:
        'BioNixus sizes the GCC vaccine market at roughly USD 1.18 billion in 2026, advancing toward about USD 2.06 billion by 2030 at roughly 17.9% CAGR. Saudi Arabia and the UAE account for the majority of value; Kuwait, Qatar, Bahrain, and Oman contribute smaller but structurally distinct ministry-led volumes. Pair this page with the Saudi Arabia and UAE vaccine market reports for country depth.',
    },
    {
      question: 'Which GCC countries drive vaccine volume?',
      answer:
        'Saudi Arabia leads via the National Immunization Program and Hajj/Umrah mandatory vaccination. The UAE follows with a dual public–private and travel-vaccine mix. Kuwait (~USD 44M), Qatar (~USD 49M), Oman (~USD 24M), and Bahrain (~USD 20M) in 2026 add childhood-schedule and adult-expansion demand through ministry channels.',
    },
    {
      question: 'How does BioNixus support Gulf vaccine teams?',
      answer:
        'BioNixus designs bilingual GCC vaccines programmes: schedule and tender intelligence, pilgrimage and travel-demand sizing, cold-chain and access-risk maps, and KOL mapping tied to real public-health influence. Begin from the healthcare market research hub or request a scoped briefing through the contact page.',
    },
  ],
};
